GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OTCPK:ZLDPF) » Definitions » Cyclically Adjusted PS Ratio

Zealand Pharma A/S (Zealand Pharma A/S) Cyclically Adjusted PS Ratio : 117.79 (As of May. 22, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S Cyclically Adjusted PS Ratio?

As of today (2024-05-22), Zealand Pharma A/S's current share price is $90.70. Zealand Pharma A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $0.77. Zealand Pharma A/S's Cyclically Adjusted PS Ratio for today is 117.79.

The historical rank and industry rank for Zealand Pharma A/S's Cyclically Adjusted PS Ratio or its related term are showing as below:

ZLDPF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 13.51   Med: 34.98   Max: 132.23
Current: 114.1

During the past years, Zealand Pharma A/S's highest Cyclically Adjusted PS Ratio was 132.23. The lowest was 13.51. And the median was 34.98.

ZLDPF's Cyclically Adjusted PS Ratio is ranked worse than
96.65% of 507 companies
in the Biotechnology industry
Industry Median: 5.56 vs ZLDPF: 114.10

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zealand Pharma A/S's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.036. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.77 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Zealand Pharma A/S Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Zealand Pharma A/S's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Cyclically Adjusted PS Ratio Chart

Zealand Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.42 35.15 24.97 39.47 67.03

Zealand Pharma A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.48 48.62 54.83 67.03 129.60

Competitive Comparison of Zealand Pharma A/S's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Zealand Pharma A/S's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma A/S's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's Cyclically Adjusted PS Ratio falls into.



Zealand Pharma A/S Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Zealand Pharma A/S's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=90.70/0.77
=117.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zealand Pharma A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Zealand Pharma A/S's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.036/118.4000*118.4000
=0.036

Current CPI (Mar. 2024) = 118.4000.

Zealand Pharma A/S Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.035 99.700 0.042
201409 0.442 99.700 0.525
201412 0.045 99.400 0.054
201503 0.041 100.200 0.048
201506 0.047 100.300 0.055
201509 0.047 100.200 0.056
201512 1.031 99.800 1.223
201603 0.042 100.200 0.050
201606 0.050 100.600 0.059
201609 0.248 100.200 0.293
201612 0.980 100.300 1.157
201703 0.427 101.200 0.500
201706 0.059 101.200 0.069
201709 0.220 101.800 0.256
201712 0.052 101.300 0.061
201803 0.052 101.700 0.061
201806 0.077 102.300 0.089
201809 0.000 102.400 0.000
201812 0.065 102.100 0.075
201903 0.000 102.900 0.000
201906 0.095 102.900 0.109
201909 0.045 102.900 0.052
201912 0.047 102.900 0.054
202003 0.051 103.300 0.058
202006 0.898 103.200 1.030
202009 0.226 103.500 0.259
202012 -0.395 103.400 -0.452
202103 0.022 104.300 0.025
202106 0.137 105.000 0.154
202109 0.199 105.800 0.223
202112 0.047 106.600 0.052
202203 0.038 109.900 0.041
202206 0.081 113.600 0.084
202209 0.126 116.400 0.128
202212 0.067 115.900 0.068
202303 0.038 117.300 0.038
202306 0.026 116.400 0.026
202309 0.702 117.400 0.708
202312 0.058 116.700 0.059
202403 0.036 118.400 0.036

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Zealand Pharma A/S  (OTCPK:ZLDPF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Zealand Pharma A/S Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma A/S (Zealand Pharma A/S) Business Description

Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.